The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow.
Since the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists.
Pors
Klaus
K
Institute of Cancer Therapeutics, School of Life Sciences, University of Bradford, West Yorkshire BD7 1DP, UK. k.pors1@bradford.ac.uk
Goldberg
Frederick W
FW
Leamon
Christopher P
CP
Rigby
Alan C
AC
Snyder
Scott A
SA
Falconer
Robert A
RA
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002625:Chemistry, Organic / Q000639:trends; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D055808:Drug Discovery / Q000191:economics / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents